HC Wainwright Cuts Aprea Therapeutics (NASDAQ:APRE) Price Target to $1.20

Aprea Therapeutics (NASDAQ:APRE) had its target price reduced by HC Wainwright from $4.00 to $1.20 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

APRE has been the subject of a number of other reports. Wedbush decreased their price target on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating for the company in a research note on Tuesday, February 10th. Zacks Research upgraded Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.10.

Aprea Therapeutics Price Performance

Aprea Therapeutics stock opened at $0.72 on Tuesday. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.22. The firm has a market capitalization of $8.19 million, a P/E ratio of -0.36 and a beta of 1.47. The company’s 50-day moving average is $0.75 and its 200 day moving average is $1.04.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Monday, March 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06. The business had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. Research analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.67% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.